CD38 and neoplasm: A potential obstacle to CD38's use as an MM target is its expression on T cells; however, a preclinical study has shown that T cell fratricide does not preclude the efficacy of anti-CD38 BsAbs as long as tumor cells are lysed at a higher or equal rate to T cells (18).